Telix Pharmaceuticals Limited
ACN 616 620 369
Suite 401, 55 Flemington Road
North Melbourne
Victoria, 3051
Australia

Telix Pharmaceuticals 4th Annual General Meeting of Shareholders Results of Meeting

Melbourne (Australia) – 12 May 2021. Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) is pleased to advise that each of the resolutions put to the Annual General Meeting was passed.

All resolutions were determined by Poll.

The results provided in the attached document are provided in accordance with Listing Rule 3.13.2 and section 251AA of the Corporations Act.

About Telix Pharmaceuticals Limited

Telix is a clinical-stage biopharmaceutical company focused on the development of diagnostic and therapeutic products using Molecularly Targeted Radiation (MTR). Telix is headquartered in Melbourne, Australia with international operations in Belgium, Japan, and the United States. Telix is developing a portfolio of clinical-stage products that address significant unmet medical needs in oncology and rare diseases. Telix is listed on the Australian Securities Exchange (ASX: TLX). For more information visit www.telixpharma.com and follow Telix on Twitter (@TelixPharma) and LinkedIn.

Telix Corporate Contact

Dr. Christian Behrenbruch
Telix Pharmaceuticals Limited
Managing Director and CEO
Email: chris.behrenbruch@telixpharma.com

Telix Corporate Communications

Dr. Stewart Holmstrom
Telix Pharmaceuticals Limited
Director of Corporate Communications
Email: stewart.holmstrom@telixpharma.com

LINK Market Services

TELIX PHARMACEUTICALS LIMITED

RESULT OF ANNUAL GENERAL MEETING (ASX REPORT)

ANNUAL GENERAL MEETING
Wednesday, 12 May, 2021

As required by section 251AA(2) of the Corporations Act 2001 (Commonwealth) the following statistics are provided in respect of each resolution on the agenda.

Resolution Voted on at the meeting			Proxy Votes (as at proxy close)				Poll (Manner in which votes were cast in person or by proxy on a poll (where applicable) on a poll at the meeting			
No	**Short Description**	**Strike Y/N/NA**	***For***	***Against***	***Discretionary (open votes)***	***Abstain***	***For***	***Against***	***Abstain *****	***Result***
1	ADOPTION OF THE REMUNERATION REPORT	N	80,197,547 97.97%	612,453 0.75%	1,045,667 1.28%	432,594	82,249,204 99.26%	612,453 0.74%	452,594	Carried
2	RE-ELECTION OF DR ANDREAS KLUGE AS DIRECTOR	NA	102,679,827 92.65%	7,096,688 6.40%	1,045,667 0.94%	192,329	129,426,484 94.80%	7,096,688 5.20%	192,329	Carried
3	APPROVAL OF ISSUE OF OPTIONS TO DR CHRISTIAN BEHRENBRUCH	NA	77,142,055 95.86%	2,287,948 2.84%	1,045,667 1.30%	234,177	78,860,419 96.78%	2,622,948 3.22%	234,177	Carried
4	APPROVAL OF AGGREGATE REMUNERATION FOR NON-EXECUTIVE DIRECTORS	NA	80,290,273 97.91%	670,625 0.82%	1,045,667 1.28%	281,696	82,341,930 99.19%	670,625 0.81%	301,696	Carried
5	APPROVAL OF ISSUE OF SHARES IN CONNECTION WITH THE PARTNERSHIP WITH CHINA GRAND PHARMA	NA	108,843,311 98.87%	163,714 0.15%	1,083,917 0.98%	923,569	135,628,218 99.88%	163,714 0.12%	923,569	Carried
6	APPROVAL OF ISSUE OF SHARES IN CONNECTION WITH ACQUISITION OF THERAPHARM GMBH	NA	109,664,981 98.95%	112,498 0.10%	1,045,917 0.94%	191,115	136,411,888 99.92%	112,498 0.08%	191,115	Carried
7	ADOPTION OF TELIX EQUITY INCENTIVE PLAN	NA	77,198,775 95.95%	2,210,944 2.75%	1,045,917 1.30%	254,211	79,252,389 97.29%	2,210,944 2.71%	254,211	Carried

** - Note that votes relating to a person who abstains on an item are not counted in determining whether or not the required majority of votes were cast for or against that item